Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations.

Recursion Pharmaceuticals is expected to provide updates regarding the clinical-stage pipeline programs on its second-quarter earnings call.

Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga Pro. The company reported a second-quarter loss of 41 cents per ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter.

The company also collaborated with NVIDIA Corporation, the global leader in visual computing technologies, to develop a next-generation platform for the creation of novel therapies. Recursion ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to beat earnings when it reports second-quarter 2025 results on ...